The same PSA result can mean different levels of risk to different men.
PSA testing misses 30-50 percent of aggressive prostate cancer that requires treatment.
These men are not referred for MRI and a tumour may not be detected early enough for successful treatment.
PSA testing also often leads to referring men with a low risk of Prostate Cancer for an MRI and this could lead to an unnecessary Biopsy of the Prostate when the MRI has been unable to determine whether prostate cancer is present or not.
Unnecessary Biopsies should be avoided because it can cause side effects such as blood in the Urine and faeces and, in the worst case, sepsis due to bacteria in the blood.
Stockholm3 determines risk more accurately for the individual so that men with a low risk are not sent for an MRI/Biopsy and men with a lower PSA but higher risk are not missed.
Stockholm3 does not require any special preparations such as fasting. The test can be performed at any time of the day.
The cost of Stockholm3 is £395.
It will take 2-3 weeks.
Stockholm3 was developed by researchers at the Karolinska Institutet in Stockholm, Sweden’s leading medical university and has been evaluated in clinical studies with more than 75,000 Swedish, Norwegian and Finnish men.
Your test result will indicate whether you have a low, normal, or elevated risk for prostate cancer. If you have a low or normal risk, you will be recommended another prostate cancer test in 2-6 years. if you have an elevated risk you may be referred for an MRI. Your result will be sent to your doctor and they will discuss with you the next steps
The earlier a tumour is identified, the better the chances of curing it. If the tumour is growing within the prostate (i.e. confined to the prostate), the chances of recovery are well over 95% when treated effectively. For men diagnosed with prostate cancer after it has spread outside the prostate, there is a high risk of dying from the disease. Stockholm3 is an important tool to find prostate cancer earlier.